Clinical Trials Logo

Clinical Trial Summary

Efforts to identify individuals at a higher risk for adverse cardiovascular outcomes focus on traditional risk factors, such as age, gender, smoking status, blood pressure, and cholesterol; however, this approach does not directly assess cardiovascular function and underestimates the risk of experiencing adverse cardiovascular outcomes in women. This prospective, observational trial will examine the ability of the Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease screening protocol, a series of non-invasive procedures to identify middle-aged and older women who are at elevated risk for experiencing an adverse cardiovascular event in the five-year period after screening. The predictive value of the Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease protocol will also be compared to the Framingham Risk Score to determine if one method has better sensitivity for estimating risk for an adverse cardiovascular outcome.


Clinical Trial Description

Every seven minutes in Canada, there is a death due to heart disease or stroke. Up to 80% of cardiovascular disease (CVD) could be prevented by identifying and controlling for biological risk factors such as hypertension, high cholesterol, and diabetes, and behavioral risk factors such as physical inactivity, unhealthy diet, and smoking. Efforts to identify individuals at a higher risk for adverse cardiovascular events, such as the Framingham Disease Risk (FDR) score, focus on traditional risk factors, such as age, gender, smoking status, blood pressure, and cholesterol. While this approach does estimate 10-year risk for heart attacks,3 it remains suboptimal as it does not assess how well each individual's cardiovascular system is functioning. In fact, a previous study suggests that more than 80% of females evaluated with the FDR were identified as being at low risk, or not qualifying for medications known to lower cardiovascular risk before experiencing a myocardial infarction. Therefore, these data warrant the use of cardiovascular screening approaches that are more accurate in identifying the risk of adverse cardiovascular outcomes. There is a common perception that CVD is a 'man's disease'; however, women tend to develop heart disease approximately 10-15 years later than men, with a prevalence rate similar between sexes after ≥ 60 years of age. Heart disease is the leading cause of death in women worldwide. Women are often under-represented in cardiovascular clinical trials, which is an issue because their clinical presentation and prognosis of cardiovascular disease differs from that of men. In fact, women who suffer an acute MI are more likely to die, have an increased risk of repeat MI, develop heart failure, or consequentially suffer sudden cardiac death, as compared to men. Although improvements in CVD management have led to decreased mortality rates, more women than men have died from causes related to CVD since 1980. It is also important to highlight that traditional risk factors assessed by FDR score underestimate the risk of experiencing an adverse cardiovascular event in women, as compared to men. Thus, it appears that there is a need to develop innovative screening tools to better detect early stages of CVD risk amongst women. The Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease trial is a screening program designed to screen for cardiovascular risk in women. It was adapted from the 4-Test Rasmussen cardiovascular screening program, which was developed by Dr. Jay Cohn at the Center for Cardiovascular Disease Prevention, University of Minnesota. The 4-test screening approach utilizes non-invasive procedures to measure structural and functional changes in the large and small arteries, including elasticity of artery walls and blood pressure at rest and in response to 3-min of moderate intensity exercise. Tests are scored from 0-2 (0 = normal; 1 = borderline; 2 = abnormal) with a total RDS ranging from 0-8. Each participant is categorized based on risk (i.e. 0-2 = normal; 3-8 = abnormal). These simple, non-invasive procedures aim to detect early stages of CVD for individual asymptomatic patients. However, these tests are not yet available in the primary care setting and have not been used in a Canadian clinical context. Moreover, it is not known if this screening approach and other protocols are feasible and have sufficient predictive value within the context of the Canadian health care system, where health services in Canada are generally delivered by the private sector but funded by payments from provincial health insurance. The more comprehensive 10-test Rasmussen Disease Score (RDS), which uses, in addition to the 4-test approach, optic fundus imaging, a resting electrocardiogram, an ultrasound of the left ventricle and abdominal aorta, microalbumin, and brain natriuretic peptide, is better than the FDR at identifying individuals at risk for experiencing adverse cardiovascular events within 3-5 years.10 However, it is unknown whether the 4-test RDS (which will hereon in be referred to the Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease protocol) is a better predictor of future cardiac events than the FDR in women. It is also unknown if the Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease screening protocol can predict future adverse cardiovascular events in women. This prospective, observational study aims to: 1) determine if the Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease screening protocol identifies middle-aged and older women who are at an elevated risk for experiencing adverse cardiovascular outcomes within a five-year period after screening; and, 2) compare the sensitivity and specificity value of the Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease protocol and the FDR for predicting future adverse cardiovascular outcomes in women. The investigators hypothesize that the Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease protocol will provide better diagnostic accuracy in identifying middle-aged and older women at an elevated risk for experiencing adverse cardiovascular outcomes in the five year period post-screening, as compared to the FDR. The Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease Protocol: After patient enrollment and consent, the Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease protocol required participants to attend one appointment, which was scheduled for approximately 90 minutes. The Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease protocol involves four measurements, as follows: 1) resting blood pressure; 2) systolic blood pressure response to 3-min of moderate intensity exercise; 3) large artery elasticity assessment; 4) small artery elasticity assessment. For these measurements, the HD/PulseWave™ CR-2000 Research CardioVascular Profiling System (CV profiler) was used. This device is indicated for use in determining cardiovascular parameters in human subjects for research purposes only. Research staff were trained in the use of the HD/PulseWave™ CR-2000 Research CardioVascular Profiling System and performed all of the testing. Below each of the measures involved in the Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease protocol are described. Test 1: Resting blood pressure A blood pressure cuff attached to the CV profiler is placed on the participant's arm while they are in a supine position. A resting blood pressure of less than 120/80 mmHg is considered normal (0 RDS points), 120-139/80-89 is considered pre-hypertensive (1 RDS point) with the potential for the development of high blood pressure (hypertension). Blood pressure greater than 140/90 is considered abnormal for adults (2 RDS points). Test 2: Systolic blood pressure response to exercise The magnitude of rise in blood pressure during exercise may be an indication of early risk for developing hypertension, even if the participant's resting blood pressure is normal. After the resting blood pressure is assessed, the participant is asked to perform 3 minutes of moderate exercise on a 2-step stool according to the Dundee Step Test, or on a treadmill for those who are unable to perform the step test. Both of these exercise procedures are performed at a 5 metabolic equivalent (MET) workload. The participant then has their blood pressure measured once again in a supine position immediately following the exercise protocol. A rise in systolic blood pressure of under 30 mmHg and less than 169 mmHg absolute blood pressure is considered normal (0 RDS points), a rise of 30-39 mmHg and an absolute resting blood pressure of 170-179 is considered borderline (1 RDS point), and a rise of 40 mmHg or more and an absolute resting blood pressure of 180 mmHg or high is considered abnormal (2 RDS points). Test 3 and 4: Large and small artery elasticity To measure artery elasticity a wrist stabilizer is placed on the participant's wrist while they are in a supine position. A piezoelectric transducer, or pulse wave sensor, is then placed on the location of strongest pulsation of the radial artery adjacent to the styloid process. The CV Profiler assesses the diastolic decay and waveform transmitted to it through the sensor. Based on the modified Windkessel model, the instrument can then determine small artery and large artery elasticity. Measures from this instrument have been shown to be reproducible, with one studying finding that intra-visit measurements five minutes apart only differed by 3% and inter-visit measures one to four weeks later only differed by 4%. Scoring of normal, borderline and abnormal results for large and small arterial elasticity are based on age and gender cutoffs. Scoring the Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease protocol: Each of the tests in the 4-test RDS are scored as 0 for normal, 1 for borderline abnormal, and 2 for abnormal10. Total scores range from 0 to 8 and are used to stratify individuals into one of two risk groups: 0-2 = normal risk; ≥ 3 = moderate to high (abnormal) risk. Assessment of the Framingham Risk Score: FDR is determined based on the calculations described by D'Agostino et al. Information required for this calculation is acquired from a participant questionnaire, fasting blood sampling of high density lipoprotein and total cholesterol, and the resting blood pressure reading from the CV Profiler. Participants are asked to fast for the 12 hours prior to the blood draw at their appointment. Approximately 10 mL of blood is collected by a phlebotomist. The samples are then centrifuged so that the plasma can be separated and analyzed for total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides, and fasting glucose. Exploratory testing: A battery of additional validated cardiovascular related testing will be conducted in addition to the previously mentioned tests. Exploratory statistical analyses will examine different combinations of these test results combined with the resting blood pressure, exercise blood pressure response and arterial elasticity results in an attempt to improve the sensitivity and specificity of the Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease screening protocol. Questionnaires Participants are instructed to fill out a series of questionnaires: 1. physical activity behaviour is assessed using the International Physical Activity Questionnaire (IPAQ) short-version. This questionnaire measures the amount and intensity of physical activity completed by an individual; 2. the Cardiovascular Health in Ambulatory Care Research Team (CANHEART) Health Index is used to assess cardiovascular health behavior and disease risk based on physical activity (from the IPAQ short-version), smoking status, fruit and vegetable consumption, body mass index, as well as presence of diabetes and high blood pressure; 3. stage of change for health behaviors and stages of change specifically related to physical activity are assessed using the Transtheoretical Model of Change and the Physical Activity Stages of Change questionnaires, respectively; 4. quality of life is assessed using the EuroQol Five Dimension Five Level questionnaire; 5. presence and severity of depressive symptoms are assessed using the Patient Health Questionnaire-9. Fried Frailty Phenotype A phenotype of frailty was assessed using the Modified Fried Criteria as previously described by Fried et al. Briefly, the Fried score classifies participants as frail if three or more of the following criteria are met: 1) unintentional weight loss; 2) self-reported exhaustion; 3) weakness; 4) slow walking speed; 5) low physical activity. Exhaustion is assessed by the Center for Epidemiologic Studies - Depression Scale. Physical activity levels are assessed by the Paffenbarger Physical Activity Scale23. Unintentional weight loss is determined via a questionnaire, while the weakness and slow walking speed are assessed using a grip strength dynamometer and a five meter gait speed test, respectively. 6- Minute Walk Test Participants are instructed to walk as many lengths of a 30 meter track as possible during the 6 minute duration. Distance covered during the test is recorded. A study by Beatty et al. showed the prognostic value of the 6MWT for predicting cardiovascular events in patients with stable coronary heart disease. Adverse Cardiovascular Outcomes - 5-year follow-up Upon completion of the Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease Protocol, each individual's Personal Health Information Number (PHIN) will be utilized to follow the study participants and to determine if they experienced an adverse cardiovascular outcome, as defined in Table 2, using the Manitoba Centre for Health Policy (MCHP) Population Health Research Data Repository. This linkage will be done at Manitoba Health, which will provide MCHP with the correct scrambled identifiers needed to follow-up all participants. MCHP data will be accessed through a number of different databases. Hospital separations abstracts, medical claims and the Drug Program Information Network will be examined to provide information on hospitalizations for cardiac diseases, cardiac procedures performed, cardiac-related and other medications used, and diagnoses with cardiac diseases. This information will help examine the diagnostic accuracy of the RDS versus the FDR. Vital statistics will also provide information on cause of death to allow for mortality rate tracking. This administrative health data will be used to compare adverse cardiovascular events with the Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease protocol results to determine if this cardiovascular screening approach predicted which individuals were at moderate to high risk of an adverse cardiovascular outcome over the five-year period after screening. The investigators' rationale to access all follow-up health information from the Repository at the MCHP is to obtain the most accurate information on healthcare service utilization, adverse cardiovascular events, demographics, etc. This method is much simpler, more complete and less invasive than repeated contact with participants. Statistical analysis Based on published data, the investigators predict that 36% of the screened population (i.e. 360 of the 1000 participants) will have an abnormal outcome based on the Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease Protocol (i.e. a score of 3 or greater). This data indicates that approximately 7.7% (i.e. 28 of the 360 participants) of the people with an abnormal score will experience an adverse cardiovascular outcome in the 5-year period. Kaplan-Meier methods and Receiver Operating Characteristic curves will be conducted to estimate cumulative rates of adverse outcomes and to compare the sensitivity and specificity of the Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease protocol and the FDR score, respectively. A Cox Proportional Hazards model will be conducted, controlling for covariates identified through univariate analysis, such as age, that could be predictive of adverse cardiovascular outcomes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02863211
Study type Observational [Patient Registry]
Source St. Boniface Hospital
Contact
Status Active, not recruiting
Phase
Start date September 2015
Completion date February 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)